Lung Cancer Therapeutics Market

Lung Cancer Therapeutics Market by Disease Types (Non-small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Treatments (Radiation Therapy, Immunotherapy, Targeted Therapy, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1654
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 1
  • No. Of Pages: 173
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global lung cancer therapeutics market size is anticipated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to increasing penetration of nanomedicine to treat lung cancer and the increasing approvals of drugs across the globe.

Lung Cancer Therapeutics Market Key Takeaways

Cancer causes abnormal cell growth during mutation. This can lead to undisciplined growth of the cells from the original site through lymph and blood system to another site. Lung cancer, also known as pulmonary carcinoma. is a type of cancer that is mainly observed in the lung tissues. Exposure to asbestos, cigarette smoking, pipe smoking, and cigar smoking can cause lung cancer. This cancer can be examined by biopsy, which is carried out by using bronchoscopy, and lung cancer can be treated by chemotherapy, radiotherapy, immunotherapy, and surgery.

The lung cancer reduces the ability of lungs to supply oxygen to the bloodstream. Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and lung carcinoid tumor are the three major types of lung cancer. NSCLC is the common type of lung cancer. Around 83% of lung cancers come under NSCLC. Coughing, wheezing, chest pains, appetite loss, weight loss, shortness of breath, and shortness of breath are some of the common symptoms of lung cancer.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing pollution due to rapid industrialization is anticipated to drive the market growth during the forecast period.
  • Rising number of smokers is projected to boost the market expansion.
  • High efficient drugs availability is one of the major factors propelling the market growth in the coming years.
  • Increasing geriatric population and rising prevalence of unhealthy lifestyle are key factors spurring the growth of the market.
  • Targeted and ground-breaking delivery of drugs for treatment of lung cancer is projected to propel the market growth during the forecast period.
  • Rising acceptance of personalized treatments is estimated to push the market growth.
  • High cost of the drug therapies can hinder the market growth during the forecast period.
  • Poor cancer diagnostic facilities are the major factors hampering the market expansion.
  • Increasing R&D investment in new drugs is expected to create opportunities for the market growth.

Scope of the Report

The report on the global lung cancer therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Lung Cancer Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Disease Types (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Treatments (Radiation Therapy, Immunotherapy, Targeted Therapy, and others),

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Lung Cancer Therapeutics Market Segment Insights

Non-small Cell Lung Cancer (NSCLC) segment to constitute a major market share

On the basis of disease types, the market is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The NSCLC segment is expected to account for a major market share in the projected timeline. NSCLC is the common type of lung cancer. About 85% of the lung cancer patients in the UK have NSCLC type of cancer, according to Cancer Research 2017 data. Rising incidence of NSCLC type lung cancer is expected to drive the segment growth.

Lung Cancer Therapeutics Market By Disease Types

Radiation therapy segment is expected to register at a significant pace

In terms of treatments, the market is segmented into radiation therapy, immunotherapy, targeted therapy, and others. The radiation therapy is expected to grow at a rapid pace during the forecast period owing to the emergence of latest technology in radiation therapies. Radiation therapy kills cancer cells or slows their growth by impairing the DNA.

North America to dominate the market

On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. Lung cancer is the second most common cancer and it is the leading cause of cancer death for men and women in the US. Around 142,560 (76,650 men and 66,020 women) deaths from lung cancer occurred in the year 2019, as per American Society of Clinical Oncology 2019 report.

Lung Cancer Therapeutics Market By Regions

Segments

Segments Covered in the Report
The global lung cancer therapeutics market has been segmented on the basis of

Disease Types
  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
Treatments
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

Competitive Landscape

Key players competing in the lung cancer therapeutics market include AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Lung Cancer Therapeutics Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lung Cancer Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Lung Cancer Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Lung Cancer Therapeutics Market - Supply Chain
  4.5. Global Lung Cancer Therapeutics Market Forecast
     4.5.1. Lung Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Lung Cancer Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Lung Cancer Therapeutics Market Absolute $ Opportunity
5. Global Lung Cancer Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Lung Cancer Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
6. North America Lung Cancer Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Lung Cancer Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Lung Cancer Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
8. Europe Lung Cancer Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Lung Cancer Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Lung Cancer Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Lung Cancer Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Lung Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Lung Cancer Therapeutics Market: Market Share Analysis
  11.2. Lung Cancer Therapeutics Distributors and Customers
  11.3. Lung Cancer Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. AstraZeneca Boehringer Ingelheim Bristol-Myers Squibb Company Eli Lilly and Company
Segments Covered in the Report
The global lung cancer therapeutics market has been segmented on the basis of

Disease Types
  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
Treatments
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company

Key players competing in the lung cancer therapeutics market include AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Eli Lilly and Company.

Lung Cancer Therapeutics Market By Key Players

Buy Report